Symbols

FHTX

Foghorn·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About FHTX

Foghorn Therapeutics Inc.

A developer of therapeutics for genetically determined dependencies within the chromatin regulatory system

Industry

Biological Technology

Established Date

Listing Date

10/23/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

106

Fiscal Year Ends

12-31

Website

foghorntx.com

Security Type

Common stock

Office address

99 Coolidge Avenue, Suite 500, Watertown, Massachusetts 02472

Business

Introduction

Foghorn Therapeutics Inc., was incorporated in October 2015 as a Delaware corporation. The company is a clinical-stage precision therapy biotechnology company that is the first to develop a new class of drugs that target chromatin regulation systems to correct abnormal gene expression. Its proprietary Gene Traffic Control platform enables integrated research and targeting of the system, and its R&D pipeline focuses on oncology with potential applications in other disease areas.

Company Financials

EPS

FHTX has released its 2025 Q4 earnings. EPS was reported at -0.35, versus the expected -0.25, missing expectations. The chart below visualizes how FHTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

FHTX has released its 2025 Q4 earnings report, with revenue of 9.25M, reflecting a YoY change of 223.77%, and net profit of -21.66M, showing a YoY change of -11.08%. The Sankey diagram below clearly presents FHTX's revenue sources and cost distribution.